A subgroup analysis of a randomized trial showed that patients with previously treated metastatic renal cell carcinoma had significant improvement in progression-free survival when they received everolimus.
City of Hope | Strategic Alliance Partners
Latest from City of Hope
ASH 2010: Brentuximab Vedotin Produces High Response Rate in Relapsed or Refractory Hodgkin Lymphoma
An investigational drug known as brentuximab vedotin (SGN-35) achieved dramatic responses in a pivotal phase II study involving younger patients with relapsed or refractory Hodgkin lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5